Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin

Inclusion Criteria: * Written signed informed consent obtained before any study-related activities. * Aged 18 to 50 years inclusive, at the time of signing the ICF. * Participants who are considered to be in good general health as determined by medical evaluation including medical history, physical examination and laboratory tests within 21 days prior to enrollment. * Participants with a BMI within the range 18.5 to 35 kg/m2 inclusive at screening. * Women who are not pregnant or breastfeeding (WOCBP). * WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test before vaccination at Day 1. * Participants who are willing and able to comply with the study procedures and are in the view of the investigator capable of completing the study. Exclusion Criteria: * History of previous laboratory confirmed influenza infection in the past 12 months, excluding laboratory confirmed COVID-19 infections, prior to the day of study vaccination. * Positive (in the past, suspected or ongoing) for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV) antibody. * Past or current history of immune mediated and/or autoimmune diseases as indicated by the investigator, e.g. diabetes mellitus (type I or II, with the exception of gestational diabetes) and thyroid disease. * Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator. * Clinical conditions re…